05-Aug-2022 | Zion Market Research
The global non-alcoholic steatohepatitis biomarkers market size was worth USD 1,218.5 million in 2021 and is estimated to grow to USD 5,234.6 million by 2028, with a compound annual growth rate (CAGR) of approximately 27.5% over the forecast period.
Unhealthy fatty liver disease has a severe type known as non-alcoholic steatohepatitis (NASH). Fat buildup or deposition in the liver is the primary cause of the non-alcoholic fatty liver disease (NAFLD). NASH is the name of the fat-accumulation condition that results in inflammation and damage. The disease known as cirrhosis, which can be fatal, can result from NASH liver damage. Fatigue and a slight abdominal ache to the upper right are signs of NASH. The physical examination and medical history are crucial in diagnosing the disease. A small piece of liver tissue is sliced with a needle and examined under a microscope to diagnose liver inflammation. This procedure, sometimes referred to as a liver biopsy, offers a diagnosis for differentiating between inflammation and scarring.
In the following years, demand for non-alcoholic steatohepatitis biomarkers is likely to increase due to the rising prevalence of chronic liver disorders. Over the forecast period, the demand for noninvasive diagnostic tools is likely to increase along with patient awareness levels, which is expected to support the development of the global non-alcoholic steatohepatitis biomarkers market. The factors behind the reduced adoption of invasive procedures for disease diagnosis are the high cost of liver biopsy, invasiveness, and poor patient acceptance. NASH is challenging to diagnose, and liver biopsy is considered the gold standard for distinguishing NASH from NAFLD. However, the drawbacks of its use, such as invasiveness and expensive cost, led to a shift in preference for non-alcoholic steatohepatitis biomarkers. Over the forecast period, this is expected to fuel the market's expansion. The development of the global nonalcoholic steatohepatitis biomarkers market is being constrained by the adverse effects of NASH therapies as well as the absence of sophisticated diagnostic testing for NAFLD.
The global non-alcoholic steatohepatitis biomarkers market is segregated based on biomarker type, end user, and region. Based on biomarker type, the market is divided into serum biomarkers, biomarker panels, fibrosis biomarkers, and imaging biomarkers. As of 2021, serum biomarkers held the majority of the market. The market is categorized into hospitals, diagnostic centers, and others based on end-users. In 2021, the diagnostic center's industry dominated the market for non-alcoholic steatohepatitis biomarkers.
The global nonalcoholic steatohepatitis biomarkers market is divided into geographic regions of North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In 2021, North America led the market for nonalcoholic steatohepatitis biomarkers, and it is projected that this trend will persist over the upcoming years. The region's dominance can be attributed to the presence of important players, the growing number of NASH patients, technological improvements, awareness of the diagnosis process, a rise in obesity & type 2 diabetes, and a rise in awareness of various causes of fatty liver. Efforts by major players in R&D to create novel and promising biomarkers are expected to boost the nonalcoholic steatohepatitis biomarkers market in the North American region. The non-alcohol steatohepatitis biomarker market is expanding at the quickest rate in the Asia Pacific. The strong market growth can be attributed to the pharmaceutical industry and the rapidly growing health infrastructure. Additionally, the main demand-generating variables for nonalcoholic steatohepatitis biomarkers in this region are a greater prevalence of NASH and other liver illnesses. Additionally, when literacy rates rise, there will be a greater awareness of modern treatment and diagnosis technologies, accelerating market expansion.
Key players in the global nonalcoholic steatohepatitis biomarkers market include Biopredictive, Quest Diagnostics, Exalenz Bioscience Ltd, GENFIT, Siemens Healthineers, ONE WAY LIVER, S.L, Prometheus Laboratories Inc, and Gilead Sciences Ltd.
Browse the full “Non-Alcoholic Steatohepatitis Biomarkers Market By Biomarker Type (Serum Biomarkers, Biomarker Panels, Fibrosis Biomarkers, and Imaging Biomarkers), By End-Users (Hospitals, Diagnostic Centers, and Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/non-alcoholic-steatohepatitis-biomarkers-market
Global Non-Alcoholic Steatohepatitis Biomarkers Market is segmented as follows:
By Biomarker Type
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651